full list rate price target
earn chang report pleas see
tabl page
shift focu vrx overweight
equal weight
take opportun make rate chang across coverag
upgrad vrx overweight rais price target lower
equal weight increas bullish vrx base
view busi hit inflect point exist busi
stabil offer foundat compani enjoy growth driven
dont expect launch
blockbust base busi perform well impact lessen
year threshold success come meaning launch
vrx derm busi gotten attent arguabl meaning
contribut part busi ou launch silicon hydrogel lens
over-the-counter lumifi vyzulta overlook block tackl within
busi help grind increment profit top revenu growth
alway felt turnaround dermatolog key vrx turnaround
launch duobrii bryhali altreno provid new growth lever there
investor skeptic regard potenti sinc compon
avail gener convers dermatologist indic interest new
formul seem synergist effect strength recent ram
launch increas confid around execut vrx derm busi
benefit overhaul sinc appoint humphri lead
divis also vrx benefit greater share voic key player
gsk cut back promot medic dermatolog salix busi seem
solid foot xifaxan grow nice teva seem unlik refil
bolster confid compani initi trial new indic
prgo inabl win approv gener version proair reduc near-term
earn momentum manag previous guid contribut
even substanti contribut prgo store-brand over-the-counter busi
perform well recent though think hard investor get
comfort long-term outlook given secular chang over-the-counter space e-commerc
emerg import lever compani remain rel small
think premium valuat warrant hard see increas past
also downgrad ew reduc price target
continu see valu key pipelin asset dont expect achiev key
catalyst see greater near-term potenti small cap name
catalyst upcom fomx expect phase data
expect see approv biosimilar pegfilgrastim neulasta
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
summari rate price target earn chang report chang shown bold
barclay research share price target price shown primari list currenc ep estim shown report currenc
current fiscal year estim barclay research fiscal year estim barclay research
valuat methodolog risk
valuat methodolog target base ep estim
risk may imped achiev barclay research valuat price confid near-term
potenti acknowledg risk lack sentiment adjust back name mani high valu launch expect
especi proair delay
macro level economi recov faster pace anticip consum may return nation brand name product
instead put dollar toward less expens store brand product
valuat methodolog pt support sotp valu
risk may imped achiev barclay research valuat price failur execut early-stag novel drug
develop program failur gain approv commerci adopt novel drug larg focus gi may slow
expect due competit dynam includ approv oral administ gi drug launch uptak low price biosimilar
valuat methodolog price target base ev/ebitda ebitda
risk may imped achiev barclay research valuat price inabl meet debt pay target
combin divestitur cash flow gener well under-perform base busi includ key
product xifaxan could neg busi outlook on-going legal challeng prove costli origin expect potenti
disrupt busi perform cash gener sooner expect gener competit diversifi busi segment well risk
around gener entrant key product franchis like xifaxan
back growth final
valeant pharmaceut intern inc vrx quarterli annual ep usd
consensu number thomson reuter receiv gmt
strength vrx caught attent mani investor provid
concret evid yet compani turnaround gain momentum vrx still face
challeng compani hit import mileston deliv organ growth
first time new manag team moreov there good reason
optimist compani sustain momentum product launch across
dermatolog busi bausch lomb launch come impact
begin lessen
back offens dermatolog
rightli skeptic whether would enough revers declin
ebitda especi compani continu face howev weve begun
see much improv perform compani dermatolog busi recent
month foundat turnaround establish vrx hire humphri
brought track record success dermatolog busi merz stiefel
allergan convers physician indic sinc humpri join
vrx compani promot intens increas compani salesforc
visibl physician offic vrx step-up promot intens come time
drug compani back away medic dermatolog due loss
exclus promot product failur bring new product market allergan
glaxosmithklin bayer among name scale back presenc
turnaround vrx dermatolog busi evidenc turnaround script
volum trend sever key product product gone shrink volum
enjoy growth even modest case turnaround signific
view lower pressur new product launch base busi
perform well threshold success launch duobrii bryhali altreno
much lower dont expect vrx new product blockbust think
could achiev close new sale aggreg would suffici
potenti doubl dermatolog busi current level
think perform sever key product address concern weve
heard regard commerci potenti vrx pipelin name new product
larg repres reformul molecul market long time
newer agent categori make difficult product
captur share voic clinician focu innov product
first wed point recent success launch retin-a-micro ram
revers declin sale seen older strength product
new ram base new microspong deliveri system help control
releas tretinoin improv photost use conjunct benzoyl
peroxid commonli use treat acn clinic benefit might strike
underwhelm view commerci success seen date speak
ram like benefit lower competit intens dermatolog
retin-a-micro launch bode well duobrii bryhali
second wed highlight much improv perform elidel indic atop
dermat vrx success product come time there greater
competit categori introduct dupix biolog eucrisa
inhibitor think elidel offer road map vrx duobrii bryhali two new
lotion formul symptomat relief psoriasi succeed despit recent
introduct expens biolog convers physician point better
expect enthusiasm vrx pipelin product psoriasi one physician note
us everi patient biolog need topic treatment felt
duobrri combin halobetasol propion tazaroten would effect
vrx solodyn franchis continu face challeng due increas gener
challeng encourag trend seen onexton bode well
launch altreno
elidel perform show product grow despit
competit expens biolog
onexton improv bode well altreno acn
bausch offer name
month vrx renam bausch health compani tri rebrand
distanc past controversi howev strength bausch lomb
franchis perhap overlook market share rel small
categori contact lens busi gener revenu
outsid
bausch profil pickup recent launch vyzulta new
treatment glaucoma well recently-launch lumifi over-the-counter product
treatment eye red to-dat vyzulta script modest although think
larg reflect product part coverag expect see part
coverag come month think spur growth launch
bausch silicon hydrogel daili contact len asia predominantli china
anoth driver result believ compani gain greater scale contact len
busi opportun margin expans within bausch lomb segment
xifaxan still highlight
xifaxan report revenu growth number inflat channel
dynam improv price product institut segment specif
hepat encephalopathi volum loss relat price reset
came signific net-gain compani revenu standpoint expect
time volum return
heard concern investor regard potenti launch cosmo
pharmaceut rifamycin sv mmx product initi come market
travel diarrhea dont expect cosmo product meaning impact
xifaxan franchis sinc travel diarrhea small share total xifaxan sale
moreov sign cosmo product less efficaci
perhap importantli teva push stay paragraph iv litig
vrx suggest abl identifi path forward anda file
recal teva stay litig wake fda issu new guidanc last year
think greater burden strength like keep gener challeng away
given technic challeng cost run clinic endpoint studi
unlik teva restart litig expect investor becom comfort
durabl franchis
rais price target base ev/ebitda ebitda
estim billion prior target base roughli prior ebitda
estim consid vrx busi mix note bausch consum medic devic
busi mid-teen higher multipl busi well improv mix
compani pharmaceut busi better mix product
earli stage
commerci believ upsid multipl possibl
move sidelin ep momentum catch
co plc quarterli annual ep usd
consensu number thomson reuter receiv gmt
prgo inabl win approv gener version proair hurt earn
momentum expect compani enjoy even without proair expect
enjoy solid growth next two year arguabl visibl better
name coverag howev share trade that
alreadi reflect price there good case command valuat multipl
consid prgo busi mix that someth central debat
time dont see catalyst near-term chang dynam
debat
loss proair setback well like lost earn
contribut substanti previous model revenu
possibl depend natur could retain much
approv obtain earli though conserv model
launch modest revenu await greater detail manag
quickli address defici anda think safe assum
delay take time issu minor believ fda would simpli push
action date rather issu complet respons letter requir minor
amend compani applic get review fda sinc proair
prioriti applic first-tim gener major amend would undergo
month review depend whether pre-approv inspect need
assum delay protract suspect retain first-to-market
posit lupin file anda march case dismiss could
result settlement think that unlik sinc neither parti disclos
agreement believ cipla pursu proair along hfa product
dont believ theyv submit anda yet
even setback proair expect abl make guidanc
suspect chci busi abl deliv upsid base upsid
margin addit anoth undisclos gener launch backfil
loss proair mani model though launch includ compani guidanc
gener price improv rel concentr prgo gener
busi like mean stand benefit less diversifi gener player
proair setback catalyst downgrad ew consid loss earn
momentum wed inclin stick recommend felt prgo
core store-brand busi set acceler howev think someth
prove term chcha busi consid headwind face brick mortar
retail prgo core custom base growth good year base
strong flu season well full-year benefit last fall launch store-brand nexium
howev strength flu season nexium creat tough comparison
compani abl grow base consid manag impli
growth remaind year unlik chang mind appreci there
like conservat embed guidanc manag could ultim
continu deliv growth consist seen trail month
visibl ccha growth sustain even acceler level think
investor unwil pay premium enjoy long-
term believ compani leverag e-commerc signific opportun one
see particularli well-suit compani store-brand franchis still
earli inning
lower price target base new ep estim
previou target base ep estim
step sidelin wait opportun
protagonist quarterli annual ep usd
consensu number thomson reuter receiv gmt
continu see signific valu ptgx platform continu like
opportun realiz failur
interim analysi phase trial like take time investor come back
name importantli well capit compani continu advanc
pipelin still catalyst horizon dont expect investor revisit stori
next year
still early-stag compani think manag done nice job
diversifi portfolio setback leav cupboard bare ptg-
remain attract opportun similar went proven
target also goe valid target expect disclos
addit pipelin asset later year although preclin
perhap ptgx interest asset hepcidin mimet
use treatment iron overload diseas hepcidin natur hormon
master regul iron homeostasi could use condit associ
low hepcidin level particular -thalassemia orphan condit
show dose-rel reduct serum iron level normal healthi volunt despit
promis data still await data actual patient wont occur next
lower price target base updat sotp valuat prior
target base sotp carri valu
npv shift base updat expect around time
mileston partnership acknowledg could shift gain
addit inform remov model time
although think program could potenti reviv pend review data
phase trial
new sotp base npv valuat
risk-adjust program valuat could chang base
greater probabl success greater better visibl commerci outlook
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight core busi show
evid stabil even growth expect vrx
show improv result benefit
upcom product launch duobri
potenti sale compani
faster expect adopt key product
launch would drive confid vrx long-term
investor confid vrx abil improv
near-term downsid would come poor launch
pipelin product addit gener
challeng vrx xifaxan franchis would hurt
equal weight remain construct
long-term outlook core store-brand
busi near-term medium-term
expect see acceler revenu
growth believ need move share higher
think long-term opportun e-
commerc signific take time play
see upsid acceler demand store-
brand product base macro econom condit
opportun capit deploy
risk includ inabl launch new product
on-tim unfavor season trend would
result lower sale drive multipl
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight see valu peptid
discoveri platform mean reduc time
develop novel target treatment potenti
oral deliveri howev unexpect setback
expect investor come back
compani approach catalyst
pipelin asset next year
upsid would come faster expect
develop well investor
enthusiasm anoth oral peptid drug
treatment gi condit expect
compani provid addit inform later
year
downsid event compani execut
develop timelin especi ptg-
dougla tsao herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
